Generic version of Risperdal gains FDA OK

Teva won approval for a generic version of the popular anti-psychotic drug

Mental health videos

Loneliness may be contagious
Dec. 1: New study finds that the feeling of loneliness may spread like a cold. Dr. Nancy Snyderman gives her take on this study and more in “The Spin Doctor.”

Magnetic depression therapy

Surviving family time during the holidays

For Alzheimer's patients, a painting is worth 1,000 memories

Medical pot for ADHD?

updated 7:25 p.m. ET June 30, 2008

NEW YORK - Johnson & Johnson's blockbuster anti-psychotic drug Risperdal will face generic competition, as Teva Pharmaceutical Industries Ltd. on Monday became the first company to receive approval for a generic version.

Israel-based Teva received Food and Drug Administration approval for a generic version of the blockbuster drug, used to treat schizophrenia and bipolar disorder, among other conditions. New Brunswick, N.J.-based Johnson & Johnson's Janssen unit had expected Risperdal's patent expiration this month, followed by tough generic competition over the key revenue driver.

advertisement | your ad here